<span>Image Analysis</span>
May 20, 2021

Image Analysis

Analysis of biomedical imaging data is no less a task than the image acquisition itself. Due to the complex nature of such data and variability across different subjects, information extraction has largely remained a time-consuming process. Vendors of imaging instruments and specialty software offer a variety of tools; however, a user still needs to work through a series of complicated and time sapping procedures for image analysis involving extensive manual operations. It is not just tedious, it is prone to error. The evolvement of image analysis has seriously lagged behind the rapid advancement of imaging technology.
<span>Choosing the Best Pathway for CDx Development and Commercialization</span>
May 20, 2021

Choosing the Best Pathway for CDx Development and Commercialization

Drug developers are increasingly incorporating a CDx development (companion diagnostic) strategy into their programs to deliver safer, more effective and appropriate therapies to the right patients. While the end result can be significantly beneficial for patients, and development partners, the path from analytical and clinical validation to demonstrating clinical utility and obtaining regulatory approval is often challenging. It requires a comprehensive understanding of clinical trial design, regulatory submission strategies both for the therapy and the diagnostic assay, and also a line of sight for successful commercialization.
<span>Evaluating New Antiviral and Antibiotic Drug Candidates</span>
February 18, 2020

Evaluating New Antiviral and Antibiotic Drug Candidates

The development of anti-infective treatments to combat illnesses caused by viral and microbial agents has witnessed many unique advances, most notably in the fights against bacterial infections, hepatitis and HIV. The momentum in this exciting area continues with new tools and methods to better support the development journey. 
<span>Addressing the Drug Development Gap in China</span>
May 4, 2024

Addressing the Drug Development Gap in China

Each year, new medicines are launched globally but few are available to Chinese patients,  in comparison to those in the US or EU. Drug developers are working to reduce this gap and expand the reach of new molecular entities (NMEs) so that they can improve healthcare to patients in need. Confronting this issue requires navigating the evolving regulatory environment in China and capitalizing on parallel development opportunities in the global market.
<span>PET Quantification of Receptor Occupancy</span>
February 20, 2024

PET Quantification of Receptor Occupancy

The use of PET imaging to detect and quantify receptor occupancy (RO) has become a translational standard in CNS discovery and clinical trials. For example, 18F radiolabeling of targeted small molecules enables a PET tracer-based PD biomarker. The tracer can be used for dynamic, non-invasive quantification of percentage RO.
<span>The Evolution of Open-Label Extensions and Rare Disease Studies</span>
February 18, 2020

The Evolution of Open-Label Extensions and Rare Disease Studies

When running early development studies, sponsors must consider whether or not to provide open-label, long-term treatment at the end of their randomized, placebo-controlled trial. In the past, sponsors have been hesitant to offer open-label extensions. But with our industry’s increasing focus on patient-centric care, sponsors are now weighing their options to incorporate more patient input into early development, especially when working with promising novel treatments in rare disease studies.
<span>Accelerating Rare Disease and Orphan Drug Development: Opportunities for Biomarkers, Diagnostics & Patient Engagement</span>
May 19, 2021

Accelerating Rare Disease and Orphan Drug Development: Opportunities for Biomarkers, Diagnostics & Patient Engagement

Rare diseases affect more than 350 million people worldwide but patients often face limited options for approved therapies. As a result, many patients have joined advocacy groups first and foremost to connect with others struggling with their rare disease, but also to promote research, unite multiple stakeholders and stimulate new possibilities in the therapeutic pipeline. Research and orphan drug development efforts are starting to follow suit by increasingly incorporating patients’ needs and examining potential outcomes.
<span>Capitalizing on Global Drug Development Opportunities from China</span>
January 6, 2024

Capitalizing on Global Drug Development Opportunities from China

The Chinese pharmaceutical market continues to grow steadily, but drug developers in China face similar challenges as their global counterparts: Development times are increasing and success rates are declining. Xiaoning Guo, PhD, PMP, clinical development program director of our Asia Pacific services, recently discussed potential strategies to improve investment returns and accelerate global development.
<span>What Are the Emerging Noninvasive Biomarkers in NASH?</span>
July 26, 2021

What Are the Emerging Noninvasive Biomarkers in NASH?

Novel biomarkers represent a promising means to improve diagnosis of nonalcoholic steatohepatitis (NASH). Currently, a definitive diagnosis requires a liver biopsy, a surgical procedure with many limitations. There are a variety of biomarkers that can assess liver status, but they do not always distinguish between patients with NASH and those with other disorders. Advanced imaging techniques, while useful for evaluating some liver features, can be impractical and costly.